View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 22, 2021

FAU team develops new method to forecast Covid-19 trial outcome

The study showed that computational techniques could help distinguish between finished and stopped Covid-19 trials.

A research team at Florida Atlantic University (FAU)’s College of Engineering and Computer Science in the US has created a new technique to predict if a Covid-19 trial will conclude or cease.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

The method leverages machine learning algorithms and ensemble learning.

According to the research, features are available for clinical trial reports, including features to model trial management, information and design, eligibility, keywords and drugs among others.

In addition, the study demonstrated that computational techniques could provide effective models to help distinguish between completed and cessation Covid-19 trials.

These models can further predict trial status with acceptable precision, the researchers noted.

Randomised trials are conducted to gather safety and efficacy data and to understand the new and evolving SARS-CoV-2 virus.

As of 15 July 2021, approximately 6,180 Covid-19 trials have been registered via ClinicalTrials.gov, the US registry for both private and public-funded trials performed globally.

Information on which trials will be successful is considered vital.

As Covid-19 is a relatively new disease, a small number of trials have been formally terminated, and hence the FAU team considered terminated, withdrawn and suspended studies as cessation trials.

FAU department of computer and electrical engineering and computer science professor Xingquan Hill said: “The main purpose of our research was to predict whether a Covid-19 clinical trial will be completed or terminated, withdrawn or suspended.

“If we can predict the likelihood of whether a trial might be terminated or not down the road, it will help stakeholders better plan their resources and procedures.”

The research team gathered 4,441 Covid-19 trials from ClinicalTrials.gov and created statistics, keyword, drug and embedding features. A total of 693-dimensional features were designed to signify each trial.

It was observed that keyword features obtained from the medical subject heading terms of the trial reports were the most insightful to predict Covid-19 studies.

The National Science Foundation award funded the research.

 

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena